Overexpression of c-Met has been validated as an oncogenic driver in tumorigenesis, especially in the development of invasive and metastatic phenotypes, such as NSCLC, hepatocellular carcinoma (HCC), and gastric cancer (GC). The gene discussed is MET; the disease is hepatocellular carcinoma.